top of page

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...
JMG Logo transparent.png
Executive Spotlights

Emalex Biosciences Announces $250 Million Financing to Advance New Drug for Tourette Syndrome

  • Nov 9, 2022
  • 1 min read

Chicago, IL, November 3, 2022 (PRNewswire) -- Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome.


Read full article here.

 
 
 

Recent Posts

See All
Qlaris Bio Appoints Fred Guerard as CEO

Dedham, MA, March 1, 2026 (Business Wire) -- Qlaris Bio has appointed Fred Guerard, Pharm.D., as president and chief executive officer, effective March 1, 2026, and he will also join the company’s b

 
 
 

Comments


Life Science Headlines
bottom of page